HC Wainwright initiates coverage on Seres Therapeutics with Buy rating
HC Wainwright & Co. analyst Matthew Keller initiated coverage on Seres Therapeutics with a Buy rating and a price target of $12, signaling a positive outlook.
*this image is generated using AI for illustrative purposes only.
HC Wainwright & Co. analyst Matthew Keller has initiated coverage on Seres Therapeutics with a Buy rating and a price target of $12. The rating reflects a positive outlook on the company's performance and future prospects.
Analyst Details
The coverage initiation was led by analyst Matthew Keller at HC Wainwright & Co. The firm assigned a Buy rating to Seres Therapeutics, indicating confidence in the stock's potential.
Price Target
HC Wainwright & Co. set a price target of $12 for Seres Therapeutics. This target provides a benchmark for investors regarding the stock's expected valuation.
What specific catalysts does HC Wainwright expect to drive Seres Therapeutics' stock toward the $12 price target?
How might Seres Therapeutics' upcoming clinical trial results influence investor sentiment and analyst ratings?
What competitive advantages does Seres Therapeutics have over other companies in the microbiome therapeutics space?
16
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
